Clinical Trial

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors who are refractory to, intolerant of, or ineligible for standard of care.
Protocol Amendment History 1 change
critical Primary endpoint(s) modified 2026-06-09
Trial Details
NCT Number NCT07623642
Lead Sponsor GV20 Therapeutics
Conditions Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Cholangiocarcinoma, Gallbladder Neoplasms, Colorectal Neoplasms +3 more
Enrollment 227 participants
Start Date 2026-06-02
Primary Completion 2028-06-15 (estimated)
Study Completion 2029-08-15 (estimated)
Updated on ClinicalTrials.gov 2026-06-08